NCT07218926 2026-04-03
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
GlaxoSmithKline
IDRX, Inc., a wholly owned subsidiary of GSK, LLC